Proctitis is characterized by the inflamed lining tissue of the inner rectum due to several medical conditions. The common causes of proctitis are sexually-transmitted infections (STIs), inflammatory bowel diseases (ulcerative colitis and Crohn’s disease), anal trauma, rectal infections, and radiation therapy for ovarian, anal, rectal, or prostate cancer. Tenesmus; pain in rectum, anus, and abdominal region; bleeding from rectum; watery diarrhea; mucus discharge from rectum; and loose stools are some of the symptoms of proctitis. The standard treatments available for proctitis are medications which includes anti-inflammatory drugs, antibiotics, antifungals, and immunosuppressants. Some of the major companies operating in the proctitis pipeline arena includes Synedgen Inc. and Innovation Pharmaceuticals Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.